Treatment Of Adenomyosis With Levonorgestrel-releasing Intrauterine System(LNG-IUS)

Objective: Adenomyosis is a common benign gynecological disease, which was possessed of the characters, such as infiltration, proliferation and migration that the malignancy has. Recent years have seen the increasing morbidity and younger age of onset.The typical clinical manifestation includes increasing menstruation, longer menstrual period and progression of dysmenorrhea, which will severely influence the regular work and life of the females. Besides the radical operation, there is no efficient clinic treatment. This paper offers a retrospective comparative analysis of the curative effect of 58 cases of patients with adenomyosis who received the treatment to expound on the clinical effects and security of curing adenimyosis with levonorgestrel releasing intrauterine system(LNG-IUS).Methods: 58 cases of patients with adenomyosis going to Jinzhou Obstetrics and Gynecology Hospital from June 2013 to March 2014 were collected as the research object. All these patients demanded conservative treatment and currently had no desire of fertility.According to their wills, the patients were provided with levonorgestrel releasing intrauterine system or Marvelon, an oral contraceptive for treatment. The patients were randomly divided into 2 groups. There were 36 patients willing to choose the levonorgestrel releasing intrauterine system and 22 to choose the oral contraceptive. The pre-treatment age, degree of dysmenorrhea, menstrual quantity score, CA125 level and the size and volume of uterus were of no statistical significance(p>0.05), thus testifying to their comparability. The degree ofdysmenorrhea, menstrual quantity, CA125 level and the change of uterus volume after 1, 3and 6 months of treatment, together with their improvement extent, were compared with that before the treatment in these two groups.Results: ① After 1, 3 and 6 months of treatment in these two groups, the dysmenorrhea was obviously alleviated compared with that before treatment, which was of statistical significance(p<0.05). A comparison between the two groups showed that the relief level of dysmenorrhea in the insertion group was more obvious than that in the group taking the medicine, which was of statistical significance(p<0.05); ② The menstrual quantity in these two groups after 1, 3 and 6 months of treatment reduced compared with that before treatment,which was of statistical significance(p<0.05). The comparison between these two groups revealed the fact that the reduction degree of menstrual quantity in the insertion group was more obvious that that of the group taking the medicine, demonstrating the statistical significance(p<0.05). ③ The CA125 level after one month of treatment in the insertion group decreased compared with that before treatment, which, however, had no statistical significance(p>0.05). However, the CA125 level after 3 and 6 months of treatment reduced significantly than that before treatment, testifying to the statistical significance(p<0.05). In the group taking Marvelon, the CA125 level after one month and three months of treatment had no statistical significance( p>0.05) compared with that before treatment; however, the CA125 level after 6 months of treatment was possessed of statistical significance(p<0.05) in comparison with that before treatment. It is worth-noticing that the reduction level of CA125 level in the insertion group was obviously higher than that in the group taking Marvelon. ④In these two groups, in spite of the fact that the uterus volume after 1, 3 and 6 months of treatment decreased compared with that before treatment, the results showed no statistical significance(p>0.05).⑤ The patients from these two groups suffered no adverse reaction after treatment; for this reason, the occurrence rate of the adverse reaction was of no statistical significance(p>0.05).Conclusions: Levonorgestrel releasing intrauterine system is possessed of excellent effect in curing adenomyosis dysmenorrhea, increasing menstrual quantity and CA125 level.With better curing effect than Marvelon, it brings no adverse reaction to the patients, which is regarded as an efficient clinical curing method for adenomyosis.